Armata Pharmaceuticals Inc

For the period ended Jun 30, 2024. Filed Aug 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 13, 2024

ARMP$3.80+8.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)


· · Three Months Ended · · Six Months Ended
· · June 30, · · June 30,
· 2024 · 2023 · 2024 · 2023
Grant revenue	$—	$980	$966	$1,776
Operating expenses
Research and development	8,475	8,259	16,491	17,863
General and administrative	3,439	2,350	6,617	4,888
Total operating expenses	11,914	10,609	23,108	22,751
Operating loss	(11,914)	(9,629)	(22,142)	(20,975)
Other income (expense)
Interest income	221	46	273	64
Interest expense	(2,718)	—	(4,538)	—
Change in fair value of convertible debt	23,397	6,036	10,372	2,874
Total other income (expense), net	20,900	6,082	6,107	2,938
Net income (loss)	$8,986	$(3,547)	$(16,035)	$(18,037)
Per share information:
Net income (loss) per share, basic	$0.25	$(0.10)	$(0.44)	$(0.50)
Weighted average shares outstanding, basic	36,154,521	36,068,130	36,139,873	36,056,649
Net loss per share, diluted	$(0.25)	$(0.17)	$(0.45)	$(0.50)
Weighted average shares outstanding, diluted	58,246,626	56,544,698	58,231,978	36,056,649

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.